This post was originally published on this site Sound Biologics is launching a Phase 1 trial to test its candidate immunotherapy PSB205 in relapsed or refractory solid tumor patients, after the U.S. Food and Drug Administration cleared its investigational new drug (IND) application. The product is a combination of antibodies against the PD-1 and CTLA-4 factors…

This post was originally published on this site A new imaging technique that visualizes individual cells with high resolution may improve the understanding of key events in breast cancer development, including how and when cells turn invasive and spread elsewhere. The tool, which already has helped explain mechanisms used by cancer cells to evade treatment, was…

This post was originally published on this site EPI-7386, a new androgen receptor inhibitor, was selected as Essa Pharma‘s lead candidate therapy for metastatic castration-resistant prostate cancer (mCRPC), the company announced. The company’s decision was supported by early preclinical data recently presented at the 2019 Genitourinary Cancers Symposium in San Francisco. The poster, “Next generation…

This post was originally published on this site Gracell Biotechnologies has developed a platform, called FasT CAR-T, that is able  to manufacture its CD19-targeting CAR T-cell product in a single day, as opposed to 14 days for conventional CAR T-cell therapies. Manufacturing costs also were reduced. The low-cost treatment, the company says, also is safe…

This post was originally published on this site Bluebird bio has officially opened a facility in Durham, North Carolina, to make the lentiviral vector needed for its investigational gene and cell treatments, including the CAR T-cell therapies bb2121 and bb21217 for relapsed or refractory multiple myeloma. Some 50 researchers, engineers and others are employed at the 125,000-square-foot facility. Roughly…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved a combination of Keytruda (pembrolizumab) plus Inlyta (axitinib) for the initial treatment of patients with advanced renal cell carcinoma, the most common type of kidney cancer. The approval comes only two months after the combination received priority review…

This post was originally published on this site Ccheck, a new test for early cancer detection under development by Anixa Biosciences, was able to identify patients with aggressive prostate cancer, and helped decide who should be recommended for a prostate biopsy, potentially reducing the number of unnecessary biopsies, the company announced. The test may be…

This post was originally published on this site Harpoon Therapeutics has begun dosing participants in its Phase 1/2a trial evaluating the investigational immunotherapy HPN536 in patients with advanced cancers that produce the mesothelin protein. The study (NCT03872206) will first enroll 20 ovarian cancer patients to determine the treatment’s safety and the best therapeutic dose. Then,…

This post was originally published on this site Patients with AIDS-related lymphoma have better survival outcomes when standard chemotherapy is added to their combined antiretroviral therapy (cART), a new study shows. The study, “The clinical features and prognosis of 100 AIDS-related lymphoma cases,” was published in Scientific Reports. Human immunodeficiency virus (HIV) infection is known…

This post was originally published on this site My family and I stopped to look at art this week. While we wandered among sculptures, someone smashed the window of our truck and stole our stuff: all three passports, two cameras, and lots of clothes. Most devastatingly, though, they got my laptop. The book I’ve been…

This post was originally published on this site Maintenance therapy with Ninlaro (ixazomib) can prolong and boost therapeutic responses from initial treatment in multiple myeloma patients who did not undergo an autologous stem cell transplant, a study says. The study, “Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies,” was…

This post was originally published on this site GlycoMimetics is planning a clinical trial testing its therapy candidate GMI-1359 as a treatment for breast cancer patients whose tumors have spread to the bones, the company announced. GMI-1359 is a small molecule that simultaneously targets E-selectin and CXCR4, two adhesion molecules —  cell surface proteins that…